Krystal Biotech Reports Q3 2026 Results with $127.3 Million VYJUVEK Revenue
Krystal Biotech (KRYS) reported strong third-quarter 2026 financial results, headlined by VYJUVEK global revenue of $127.3 million, a 30% increase year-over-year. While net income per diluted share fell to $2.05 from $2.66 in the prior year period, the company maintains a robust liquidity position with $1.2 billion in cash and investments. The company also authorized a new $400 million share repurchase program to be deployed over the next two years. Operational growth was driven by US net revenue of $95.3 million and expanding international markets, including Europe and Japan. Despite strong commercial performance, management noted some headwinds, including slower-than-anticipated enrollment in the EMERALD-1 study for neurotrophic keratitis due to strict eligibility criteria. However, the company lowered its non-GAAP expense guidance for R&D and SG&A, signaling improved operational efficiency.
Topics: guidance net income product performance revenue growth share repurchase program